SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE Inc is forecasted to generate positive EBITDA in 2026, supported by management's expectation of 12.5% growth in operating expenses while maintaining robust revenue momentum, evidenced by a 42% acceleration in US growth at the midpoint on a two-year revenue stack. The company is poised for continued expansion in the minimally invasive surgical implant market, as it captures market share in the sacroiliac joint fusion space, particularly with promising new product adoptions such as Granite and TORQ, which leverage a growing trend of outpatient surgical center utilization. Additionally, a strong net cash balance of $110 million as of 3Q25 provides SI-BONE with flexibility and opportunities for strategic investments, potentially enhancing their growth trajectory and solidifying their competitive position in the industry.

SI-BONE Inc. has indicated a potential decline in gross margins to 78%, attributed to pricing pressures stemming from a shift toward lower average selling price cases in deformity and trauma applications. The company's bear case scenario projects only low-teens revenue growth in the U.S. and ongoing international weakness, with expected earnings per share losses of -$0.11 despite beating consensus expectations. Additionally, SI-BONE's enterprise value relative to sales growth stands at 0.19x, significantly lower than the median of 0.34x for its small- to mid-cap peers, highlighting concerns about its competitive position and market dynamics.